Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769390 | 0.90 | TRPV4 (0.36) | HDAC6HRH3HDAC3HDAC1DRD2 | |
| SCHEMBL768103 | 0.85 | HRH3 (0.41) | HRH3DRD2HTR1A | |
| SCHEMBL768843 | 0.85 | HRH3 (0.34) | HRH3HDAC3HDAC1CCR3DRD2 | |
| SCHEMBL381136 | 0.84 | CHRM3 (0.48) | — | |
| SCHEMBL768889 | 0.83 | CHRM2 (0.39) | HDAC6HRH3 | |
| SCHEMBL769264 | 0.83 | CHRM2 (0.39) | HDAC6HRH3DRD2HTR1A | |
| SCHEMBL769370 | 0.83 | HDAC6 (0.33) | HDAC6HRH3DRD2DRD4KCNH2 | |
| SCHEMBL769117 | 0.83 | MCHR1 (0.36) | HRH3DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL768546 | 0.83 | CCR2 (0.42) | CCR3DRD2DRD4DRD3HTR1A | |
| SCHEMBL768998 | 0.83 | HTR2A (0.35) | HRH3KCNH2HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | HDAC6 407/4885HRH3 96/4885HDAC3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.